Universe Pharmaceuticals Inc
NASDAQ:UPC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
U
|
Universe Pharmaceuticals Inc
NASDAQ:UPC
|
CN |
|
DRB Holding Co Ltd
KRX:004840
|
KR |
|
A
|
Adtraction Group AB
STO:ADTR
|
SE |
|
Roland Corp
TSE:7944
|
JP |
|
A
|
Axion Ventures Inc
OTC:AXNVF
|
CA |
Balance Sheet
Balance Sheet Decomposition
Universe Pharmaceuticals Inc
Universe Pharmaceuticals Inc
Balance Sheet
Universe Pharmaceuticals Inc
| Sep-2018 | Sep-2019 | Sep-2020 | Sep-2021 | Sep-2022 | Sep-2023 | Sep-2024 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
6
|
3
|
10
|
8
|
6
|
5
|
0
|
34
|
|
| Cash |
6
|
3
|
10
|
8
|
6
|
5
|
0
|
34
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
|
| Total Receivables |
8
|
6
|
11
|
16
|
15
|
12
|
17
|
14
|
|
| Accounts Receivables |
8
|
6
|
11
|
16
|
15
|
11
|
13
|
13
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
1
|
4
|
1
|
|
| Inventory |
8
|
3
|
2
|
2
|
2
|
3
|
2
|
2
|
|
| Other Current Assets |
0
|
0
|
0
|
24
|
18
|
4
|
2
|
4
|
|
| Total Current Assets |
22
|
12
|
23
|
50
|
42
|
25
|
52
|
54
|
|
| PP&E Net |
5
|
5
|
4
|
15
|
14
|
13
|
13
|
12
|
|
| PP&E Gross |
5
|
5
|
4
|
15
|
14
|
13
|
13
|
12
|
|
| Accumulated Depreciation |
4
|
4
|
5
|
6
|
6
|
6
|
7
|
7
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
3
|
4
|
3
|
2
|
2
|
|
| Total Assets |
28
N/A
|
18
-36%
|
29
+61%
|
70
+144%
|
60
-15%
|
42
-30%
|
68
+63%
|
69
+2%
|
|
| Liabilities | |||||||||
| Accounts Payable |
3
|
2
|
3
|
5
|
3
|
5
|
5
|
2
|
|
| Accrued Liabilities |
1
|
1
|
0
|
0
|
3
|
3
|
2
|
0
|
|
| Short-Term Debt |
3
|
3
|
4
|
4
|
7
|
5
|
0
|
7
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
6
|
2
|
|
| Other Current Liabilities |
12
|
0
|
1
|
1
|
0
|
1
|
8
|
2
|
|
| Total Current Liabilities |
18
|
5
|
8
|
11
|
13
|
14
|
20
|
13
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
|
| Total Liabilities |
18
N/A
|
5
-70%
|
8
+47%
|
11
+40%
|
13
+17%
|
14
+5%
|
22
+63%
|
13
-41%
|
|
| Equity | |||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
6
|
|
| Retained Earnings |
5
|
9
|
16
|
28
|
19
|
1
|
8
|
11
|
|
| Additional Paid In Capital |
4
|
4
|
4
|
29
|
29
|
29
|
54
|
63
|
|
| Other Equity |
1
|
0
|
1
|
2
|
2
|
2
|
1
|
2
|
|
| Total Equity |
10
N/A
|
12
+28%
|
21
+68%
|
59
+183%
|
46
-21%
|
28
-40%
|
46
+63%
|
56
+23%
|
|
| Total Liabilities & Equity |
28
N/A
|
18
-36%
|
29
+61%
|
70
+144%
|
60
-15%
|
42
-30%
|
68
+63%
|
69
+2%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|